Fibrinolysis in Normal Subjects - Comparison Between Plasminogen Activator Inhibitor and Other Components of the Fibrinolytic System

 

PDF Download Buy Article Permissions and Reprints

Summary

We analyzed fibrinolytic parameters in 20 healthy men and 20 healthy women, aged from 25 to 59, before and after 10 and 20 min venous occlusion. The 10 min post-occlusion fibrinolytic activity measured directly in diluted unfractionated plasma by a highly sensitive ¹²⁵I-fibrin plate assay correlated well with the activity of euglobulins determined by the classical fibrin plate assay (r = 0.729), but pre-stasis activities determined with these two methods did not correlate (r = 0.084). The enhancement of fibrinolytic activity after venous occlusion was mainly due to an increase of t-PA in the occluded vessels (4-fold increase t-PA antigen after 10 min and 8-fold after 20 min venous occlusion). Plasminogen activator inhibitor (PAI) activity and plasminogen activator inhibitor 1 (PAI-1)¹ antigen levels at rest showed considerable dispersion ranging from 1.9 to 12.4 U/ml, respectively 6.9 to 77 ng/ml. A significant increase of PAI-1 antigen levels was observed after 10 and 20 min venous occlusion. At rest no correlation was found between PAI activity or PAI-1 antigen levels and the fibrinolytic activity measured by ¹²⁵I-FPA. However, a high level of PAI-1 at rest was associated with a high prestasis antigen level of t-PA and a low fibrinolytic response after 10 min of venous stasis. Since the fibrinolytic response inversely correlated with PAI activity at rest, we conclude that its degree depends mainly on the presence of free PAI.

• References

• 1 Isacson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent “idiopathic” venous thrombosis. Acta Chir Scand 1972; 138: 313-319
  PubMedGoogle Scholar
• 2 Johansson L, Hedner U, Nilsson IM. A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall. Acta Med Scand 1978; 203: 477-480
  PubMedGoogle Scholar
• 3 Jørgenssen M, Mortensen JZ, Madsen AG, Thorsen S, Jacobsen B. A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis. Scand J Haematol 1982; 29: 217-223
  PubMedGoogle Scholar
• 4 Stalder M, Hauert J, Kruithof EK O, Bachmann F. Release of vascular plasminogen activator (v-PA) after venous stasis: electro- phoretic-zymographic analysis of free and complexed v-PA. Brit J Haematol 1985; 61: 169-176
  CrossrefPubMedGoogle Scholar
• 5 Korninger C, Lechner K, Niessner H, Gossinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemost 1984; 52: 127-130
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Rijken DC, Juhan-Vague I, De Cock F, Collen D. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med 1983; 101: 274-284
  PubMedGoogle Scholar
• 7 Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283
  PubMedGoogle Scholar
• 8 Tissot JD, Schneider P, Hauert J, Ruegg M, Kruithof EK O, Bachmann F. Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest 1982; 70: 1320-1323
  CrossrefPubMedGoogle Scholar
• 9 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
  CrossrefPubMedGoogle Scholar
• 10 Kruithof EK O, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
  PubMedGoogle Scholar
• 11 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392-395
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Brommer EJ P, Verheijen JH, Chang GT G, Rijken DC. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemost 1984; 52: 154-156
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
  CrossrefPubMedGoogle Scholar
• 14 Kruithof EK O. Inhibitors of plasminogen activators. In: Tissue-Type Plasminogen Activator: Biological and Clinical Aspects Kluft C. ed. CRC Press Inc; Boca Raton: 1987. In press
  Google Scholar
• 15 Paramo JA, Alfaro MJ, Rocha E. Postoperative changes in the plasma levels of tissue-type plasminogen activator and its fast-acting inhibitor. Relationship to deep vein thrombosis and influence of prophylaxis Thromb Haemostas 1985; 54: 713-716
  PubMedGoogle Scholar
• 16 Kruithof EK O, Schleuning WD, Bachmann F. Human tissue-type plasminogen activator: production in continuous serumfree cell culture and rapid purification. Biochem J 1985; 226: 631-636
  CrossrefPubMedGoogle Scholar
• 17 Kruithof EK O, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69: 460-466
  PubMedGoogle Scholar
• 18 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-Dye binding. Analytical Biochemistry 1976; 72: 248-254
  CrossrefPubMedGoogle Scholar
• 19 Kruithof EK O, Ransijn A, Bachmann F. Influence of detergents on the measurement of the fibrinolytic activity of plasminogen activators. Thromb Res 1982; 28: 251-260
  CrossrefPubMedGoogle Scholar
• 20 Kluft C. Elimination of inhibition in euglobulin fibrinolysis by use of flufenamate: involvement of C’ rinactivator. Haemostasis 1977; 6: 351-369
  PubMedGoogle Scholar
• 21 Unkeless JC, Tobia A, Ossowski L, Quigley JP, Ripkins DP, Reich E. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. J Exp Med 1973; 137: 85-111
  CrossrefPubMedGoogle Scholar
• 22 Cajot JF, Sordat B, Kruithof EK O, Bachmann F. Human primary colon carcinomas xenografted into nude mice. I - Characterization of plasminogen activators expressed by primary tumors and their xenografts. Int J Cancer 1986; 38: 719-727
  CrossrefPubMedGoogle Scholar
• 23 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48: 266-269
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 Kluft C, Trumpi-Kalshoven MM, Jie AF H, Veldhuyzen-Stolk EC. Factor XH-dependent fibrinolysis: a double function of plasma kallikrein and the occurrence of a previously undescribed factor XII- and kallikrein-dependent plasminogen proactivator. Thromb Haemost 1979; 41: 756-773
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1456
  CrossrefPubMedGoogle Scholar
• 26 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
  PubMedGoogle Scholar